97. 潰瘍性大腸炎
[臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-003130-14-IT
(EUCTR)
12/03/201205/03/2012Clinical Trial to assess the efficacy and safety of KappaproctA placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients” - CSUC-01/10 Chronic active treatment refractory ulcerative colitis
MedDRA version: 14.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Kappaproct
Product Code: DIMS0150
INN or Proposed INN: NA
Other descriptive name: NA
INDEX PHARMACEUTICALSNULLNot RecruitingFemale: yes
Male: yes
132Czech Republic;Hungary;Poland;Germany;United Kingdom;Italy
2EUCTR2011-003130-14-CZ
(EUCTR)
13/01/201214/10/2011A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentA placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients Chronic active treatment refractory ulcerative colitis
MedDRA version: 16.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Kappaproct
INN or Proposed INN: DIMS0150
Other descriptive name: DIMS0150
InDex Pharmaceuticals ABNULLNot RecruitingFemale: yes
Male: yes
120Hungary;Czech Republic;Poland;Germany;Italy;United Kingdom
3EUCTR2011-003130-14-DE
(EUCTR)
30/12/201119/09/2011A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentA placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients Chronic active treatment refractory ulcerative colitis
MedDRA version: 16.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Kappaproct
INN or Proposed INN: DIMS0150
Other descriptive name: DIMS0150
InDex Pharmaceuticals ABNULLNot RecruitingFemale: yes
Male: yes
120Czech Republic;Hungary;Poland;Germany;Italy;United Kingdom
4EUCTR2011-003130-14-PL
(EUCTR)
22/12/201110/10/2011A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentA placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients Chronic active treatment refractory ulcerative colitis
MedDRA version: 14.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Kappaproct
Other descriptive name: DIMS0150
InDex Pharmaceuticals ABNULLNot RecruitingFemale: yes
Male: yes
120Czech Republic;Hungary;Poland;Germany;Italy;United Kingdom
5NCT01493960
(ClinicalTrials.gov)
December 201112/12/2011The Efficacy and Safety of Kappaproct in Chronic Active Treatment Refractory Ulcerative Colitis PatientsA Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Kappaproct as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis PatientsColitis, UlcerativeDrug: Kappaproct;Drug: PlaceboInDex PharmaceuticalsNULLCompleted18 YearsN/ABoth131Phase 3Czech Republic;France;Germany;Hungary;Italy;Poland;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2011-003130-14-HU
(EUCTR)
14/10/201101/09/2011A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentA placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients Chronic active treatment refractory ulcerative colitis
MedDRA version: 16.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Kappaproct
Other descriptive name: DIMS0150
InDex Pharmaceuticals ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Czech Republic;Hungary;Poland;Germany;Italy;United Kingdom
7EUCTR2011-003130-14-GB
(EUCTR)
06/10/201111/08/2011A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentA placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients Chronic active treatment refractory ulcerative colitis
MedDRA version: 14.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
InDex Pharmaceuticals ABNULLNot Recruiting Female: yes
Male: yes
120Phase 3Czech Republic;Hungary;Poland;Germany;Italy;United Kingdom
8EUCTR2006-001846-15-SE
(EUCTR)
06/12/200620/10/2006A placebo-controlled, randomised, double-blind, single dose proof of concept study of Kappaproct, in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degreeA placebo-controlled, randomised, double-blind, single dose proof of concept study of Kappaproct, in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree Active ulcerative colitis in steroid refractory or steroid dependent patientsProduct Name: Kappaproct
Product Code: DIMS0150
InDex Pharmaceuticals ABNULLNot RecruitingFemale: yes
Male: yes
48Sweden